Cargando…

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?

The emergence of hypervirulent Clostridioides difficile strains has decreased the efficacy of metronidazole in the treatment of C. difficile infection (CDI). Therefore, revised guidelines no longer recommend the use of metronidazole as a first-line regimen for CDI and restrict its use for non-severe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jieun, Kim, Jinyeong, Kim, Bongyoung, Pai, Hyunjoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259900/ https://www.ncbi.nlm.nih.gov/pubmed/35706079 http://dx.doi.org/10.3947/ic.2022.0027

Ejemplares similares

Diversity of binary toxin positive Clostridioides difficile in Korea
por: Kim, Jieun, et al.
Publicado: (2023)

Association between Antibiotic Consumption and Incidence of Clostridioides difficile Infection in a Hospital
por: Kim, Bongyoung, et al.
Publicado: (2020)

Genetic Relatedness of 5-Year Isolates of Clostridioides difficile Polymerase Chain Reaction Ribotype 017 Strains in a Hospital
por: Kim, Jieun, et al.
Publicado: (2021)

Quantitative characterization of Clostridioides difficile population in the gut microbiome of patients with C. difficile infection and their association with clinical factors
por: Kim, Jieun, et al.
Publicado: (2020)

Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection
por: Zhang, Kevin, et al.
Publicado: (2021)

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

Deciphering Resistome in Patients With Chronic Obstructive Pulmonary Diseases and Clostridioides difficile Infections
por: Cho, Youna, et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Plasmid-mediated metronidazole resistance in Clostridioides difficile
por: Boekhoud, Ilse M., et al.
Publicado: (2020)

A Survey of Antimicrobial Stewardship Programs in Korea, 2015
por: Kim, Bongyoung, et al.
Publicado: (2016)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

Vancomycin vs metronidazole use for the treatment of Clostridioides difficile infection in a tertiary care hospital in Saudi Arabia
por: Alhameed, Abrar F., et al.
Publicado: (2023)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Descriptive Epidemiology of Acute Pyelonephritis in Korea, 2010–2014: Population-based Study
por: Kim, Bongyoung, et al.
Publicado: (2018)

Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections
por: Yin, Jianyi, et al.
Publicado: (2019)

Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates
por: Smits, Wiep Klaas, et al.
Publicado: (2022)

690. Analysis of high-risk antibiotics for Clostridioides difficile infections in Korean hospitals: A nationwide multi-center study
por: Kim, Bongyoung, et al.
Publicado: (2023)

Ten-year trends in antibiotic usage at a tertiary care hospital in Korea, 2004 to 2013
por: Kim, Bongyoung, et al.
Publicado: (2020)

Trend of antibiotics usage for acute pyelonephritis in Korea based on national health insurance data 2010–2014
por: Kim, Bongyoung, et al.
Publicado: (2019)

Changing Pattern of Antibiotics Usage Among Hospitalized Patients of a Tertiary Hospital in South Korea: 2004–2013
por: Kim, Bongyoung, et al.
Publicado: (2017)

Corrigendum to: Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections
por: Yin, Jianyi, et al.
Publicado: (2020)

Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model
por: Yang, Jingpeng, et al.
Publicado: (2022)

A Case of Human Immunodeficiency Virus-triggered Hemophagocytic Lymphohistocytosis Presenting with Severe Bleeding Tendency
por: Kim, Bongyoung, et al.
Publicado: (2021)

Trend of Antibiotic Usage for Hospitalized Community-acquired Pneumonia Cases in Korea Based on the 2010–2015 National Health Insurance Data
por: Kim, Bongyoung, et al.
Publicado: (2020)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

680. Comparison of Extended Duration Vancomycin Regimens for Clostridioides difficile Infection in Patients on Prolonged Antibiotic Courses
por: Garzia, Christopher, et al.
Publicado: (2023)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Recurrence and mortality following treatment for Clostridum difficile infection with metronidazole or vancomycin
por: Stevens, V, et al.
Publicado: (2015)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity
por: Di, Xiuzhen, et al.
Publicado: (2015)

Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile
por: Boekhoud, Ilse M, et al.
Publicado: (2021)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

Detection of Plasmid-Mediated Resistance to Metronidazole in Clostridioides difficile from River Water
por: Cizek, Alois, et al.
Publicado: (2022)

Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Bogdanová, Kateřina, et al.
Publicado: (2021)

Clinical and Microbiologic Characteristics of Clostridium difficile Infection Caused by Binary Toxin Producing Strain in Korea
por: Kim, Jieun, et al.
Publicado: (2013)

Comparison of Supplemented Brucella Agar and Modified Clostridium difficile Agar for Antimicrobial Susceptibility Testing of Clostridium difficile
por: Kim, Gye Hyeong, et al.
Publicado: (2014)

Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains
por: Kim, Jieun, et al.
Publicado: (2016)

488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
por: Vega, Ana, et al.
Publicado: (2018)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gn81avi4o83l6eh6mvui2vpg4q